Mapping dopaminergic function using pharmacologic Magnetic Resonance Imaging (phMRI)

Mapping dopaminergic function using pharmacologic Magnetic Resonance Imaging (phMRI) - Dopamine-MRI

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33010

Enrollment

Registered

2009-05-18

Start date

2009-03-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

kinder en jeugd psychiatrie not applicable

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy male adult volunteers, aged between 20 and 35.

Exclusion criteria

Exclusion criteria: Contraindications for MRI (e.g. osteosynthetic material, pacemaker, artificial cardiac valves); claustrophobia. Symptomatic cardiovascular disease, moderate-to-severe hypertension, hyperthyroidism, glaucoma, hypersensitivity or idiosyncrasy to sympathomimetic amines, agitation, and history of drug abuse, or use of psychotropic drugs that affect DA function, such as methylphenidate and cocaine (anamnestic). Finally, cardial conduction disorder (abnormal ECG) en renal disease (serum creatinine * 110 mmol/L).

Design outcomes

Primary

Measure	Time frame
BOLD: % change in BOLD SI from baseline (ROI) PWI: % change in ratio from baseline (ROI: rCBV/white matter rCBV) ASL: % change in CBF from baseline (ROI CBF/100 mg tissue) SPECT: DAT ratio (striatal ROI binding/binding in cerebellum)	—

Secondary

Measure	Time frame
Amphetamine Interview Rating Scale	—

Countries

Netherlands

Outcome results